• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧盟的前列腺癌早期检测:与 PRAISE-U 联合力量。

Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.

机构信息

Department of Urology, KU Leuven, Leuven, Belgium; European Association of Urology Policy Office, Arnhem, The Netherlands.

Department of Urology, Erasmus Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

出版信息

Eur Urol. 2023 Dec;84(6):519-522. doi: 10.1016/j.eururo.2023.08.002. Epub 2023 Sep 12.

DOI:10.1016/j.eururo.2023.08.002
PMID:37704541
Abstract

The European Association of Urology, together with consortium partners, has launched PRAISE-U (Prostate Cancer Awareness and Initiative for Screening in the European Union), a project involving 25 institutions across 12 countries that is funded under the EU4Health program. The aim is to reduce the morbidity and mortality of prostate cancer in EU member states via customized and risk-based screening programs.

摘要

欧洲泌尿外科学会与 consortium 合作伙伴一起发起了 PRAISE-U(欧盟前列腺癌认知和筛查倡议)项目,该项目涉及欧盟 12 个国家的 25 个机构,由欧盟 4.0 健康计划资助。其目的是通过定制化和基于风险的筛查项目,降低欧盟成员国前列腺癌的发病率和死亡率。

相似文献

1
Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.欧盟的前列腺癌早期检测:与 PRAISE-U 联合力量。
Eur Urol. 2023 Dec;84(6):519-522. doi: 10.1016/j.eururo.2023.08.002. Epub 2023 Sep 12.
2
Evolution of European prostate cancer screening protocols and summary of ongoing trials.欧洲前列腺癌筛查方案的演变及正在进行的试验总结。
BJU Int. 2024 Jul;134(1):31-42. doi: 10.1111/bju.16311. Epub 2024 Mar 12.
3
Monitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project.欧盟前列腺癌筛查监测:通过PRAISE-U项目制定关键绩效指标
EClinicalMedicine. 2025 Jan 23;80:103022. doi: 10.1016/j.eclinm.2024.103022. eCollection 2025 Feb.
4
Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium.欧盟前列腺癌早期检测的卫生政策及机会性筛查的影响:PRAISE-U联盟
J Pers Med. 2024 Jan 11;14(1):84. doi: 10.3390/jpm14010084.
5
Prostate Cancer Early Detection in the European Union and UK.欧盟和英国的前列腺癌早期检测
Eur Urol. 2025 Mar;87(3):326-339. doi: 10.1016/j.eururo.2024.07.019. Epub 2024 Aug 24.
6
Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE-U Project.在欧盟五个试点地区实施基于人群的前列腺癌筛查的风险分层方法:PRAISE-U项目方案
Eur Urol Open Sci. 2024 Oct 11;70:8-17. doi: 10.1016/j.euros.2024.09.003. eCollection 2024 Dec.
7
Epilogue: different approaches for prostate cancer screening in the EU?结语:欧盟前列腺癌筛查的不同方法?
Eur J Cancer. 2010 Nov;46(17):3120-5. doi: 10.1016/j.ejca.2010.09.038.
8
Risk calculators for the detection of prostate cancer: a systematic review.用于检测前列腺癌的风险计算器:一项系统综述。
Prostate Cancer Prostatic Dis. 2024 Sep;27(3):544-557. doi: 10.1038/s41391-024-00852-w. Epub 2024 Jun 3.
9
Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission.2020 年及以后的前列腺癌早期检测:欧盟和欧盟委员会的事实和建议。
Eur Urol. 2021 Mar;79(3):327-329. doi: 10.1016/j.eururo.2020.12.010. Epub 2020 Dec 29.
10
Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey.了解基于人群的前列腺癌早期检测项目的障碍:PRAISE-U BEST调查。
J Pers Med. 2024 Jul 15;14(7):751. doi: 10.3390/jpm14070751.

引用本文的文献

1
Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.德国前列腺癌筛查策略的成本效益分析:一项微观模拟研究。
Int J Cancer. 2025 Oct 15;157(8):1662-1679. doi: 10.1002/ijc.35513. Epub 2025 Jul 16.
2
A Comparison of Magnetic Resonance Imaging Assessment and Biopsy Outcomes with and Without Central Review in Two Swedish Regional Organized Prostate Cancer Testing Programs.在瑞典两个地区性有组织的前列腺癌检测项目中,磁共振成像评估与活检结果在有和没有中心审查情况下的比较。
Eur Urol Open Sci. 2025 Jun 5;77:32-38. doi: 10.1016/j.euros.2025.05.008. eCollection 2025 Jul.
3
Prostate cancer screening in Europe: future directions and perspectives.
欧洲的前列腺癌筛查:未来方向与展望。
Prostate Cancer Prostatic Dis. 2025 Jun 10. doi: 10.1038/s41391-025-00989-2.
4
Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE-U Project.在欧盟五个试点地区实施基于人群的前列腺癌筛查的风险分层方法:PRAISE-U项目方案
Eur Urol Open Sci. 2024 Oct 11;70:8-17. doi: 10.1016/j.euros.2024.09.003. eCollection 2024 Dec.
5
Prostate cancer screening in transgender patients Why current Canadian screening policies need to be better tailored to our patients.跨性别患者的前列腺癌筛查 为何当前加拿大的筛查政策需要更好地适应我们的患者。
Can Urol Assoc J. 2025 Jun;19(6):202-204. doi: 10.5489/cuaj.9005.
6
The Diagnostic Value of Plasma Small Extracellular Vesicle-Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models.血浆小细胞外囊泡源性CAIX蛋白在前列腺癌及临床显著性前列腺癌中的诊断价值:预测模型研究
Prostate. 2025 Jun;85(8):723-741. doi: 10.1002/pros.24879. Epub 2025 Feb 27.
7
Monitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project.欧盟前列腺癌筛查监测:通过PRAISE-U项目制定关键绩效指标
EClinicalMedicine. 2025 Jan 23;80:103022. doi: 10.1016/j.eclinm.2024.103022. eCollection 2025 Feb.
8
Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men.基于人群的有组织检测项目及常规医疗保健中社会经济因素与前列腺特异性抗原(PSA)检测之间的关联:一项针对50岁男性的基于登记册的研究
BMJ Oncol. 2024 Sep 18;3(1):e000400. doi: 10.1136/bmjonc-2024-000400. eCollection 2024.
9
Development of novel nomograms for predicting prostate cancer in biopsy-naive patients with PSA < 10 ng/ml and PI-RADS ≤ 3 lesions.用于预测PSA<10 ng/ml且PI-RADS≤3类病变的未接受活检患者前列腺癌的新型列线图的开发。
Front Oncol. 2025 Jan 7;14:1500010. doi: 10.3389/fonc.2024.1500010. eCollection 2024.
10
Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target.循环剪接因子在前列腺癌中的临床价值:SRRM1作为一种新型预测生物标志物和治疗靶点
Mol Ther Oncol. 2024 Nov 23;32(4):200910. doi: 10.1016/j.omton.2024.200910. eCollection 2024 Dec 19.